Reliance Life Sciences is a diverse and integrated biotechnology initiative of the Reliance Group of companies. The Reliance Group is India’s largest private sector enterprise, with annual revenues of US$ 66.8 billion. The Group’s activities span oil and gas exploration and production, petroleum refining, petrochemicals, polyester, plastics, organized retailing and telecom. The Group’s flagship company Reliance Industries Limited is the largest private sector company and a Fortune Global 500 company. Reliance Life Sciences is part of the Promoter Group of Reliance Industries Limited. RLS was established to develop business opportunities in medical biotechnology with key initiatives in biopharmaceuticals, pharmaceuticals, regenerative medicine, clinical research and molecular diagnostics.

Kinsa is transforming how people care for themselves, their families, and their communities using mobile technologies and products. These same products empower society with tools to track the spread of disease in real-time and stop it. Their first product is a low-cost smartphone-connected thermometer. It allows us to communicate with people who have just fallen ill. It does not simply tell the temperature, rather it transforms the way of caring of the family.

The Univfy AI Platform helps women and couples navigate their family-building options with cost-savings, greater success, and a simplified experience. Univfy combines AI/machine learning, clinical expertise, and empathy to maximize each patient’s chances of success with assisted reproductive technology such as in vitro fertilization (IVF) while increasing growth and efficiency for physicians. Univfy is the only highly-scalable AI platform to provide scientifically-validated, personalized reports that counsel patients from diverse demographics about their probability of having a baby with IVF. Through technology developed by Stanford University researchers, Univfy uses a rigorous scientific process to develop and validate prediction models and to provide essential information to support better budgeting, planning, and physician-patient shared decision-making. Its methods have been published in the top, peer-reviewed research publications, setting a gold standard for IVF success model performance metrics. Univfy has a global IP portfolio, comprising patents issued in the US and other countries.

Quest Diagnostics Investments LLC, a subsidiary of Quest Diagnostics, Inc., is an American company specializing in medical laboratories.

Structural Bioinformatics, Inc. researches proteomics and discovers drugs using genomic sequences.

BioAnalogics, Inc. is an American private company located in Portland, OR, that manufactures pharmaceutical products.

BGI Shenzhen Co., Ltd. engages in the equity investment and asset management. Its business scope includes research and development and sales of computer hardware and software and peripheral equipment technology; import and export of goods and technology; equity investment; investment in industrial development; and aquatic product farming and sales. The company was founded on August 21, 2008 and is headquartered in Shenzhen, China.

Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

Repertoire Genesis supports the realization of new diagnostic methods / therapeutic methods related to personalized medicine by utilizing T cell / B cell receptor retort analysis and neo-epithelial analysis.

Sapient Discovery is a privately help drug discovery company with proprietary capabilities for discovering novel, patentable small molecule inhibitors, blockers, antagonists, activators or agonists of protein targets independent of disease category. The management and the scientific members have extensive experience in lead discovery and optimization. While the core discovery functions are performed in the U.S., chemistry facilities are utilized from India with their partner companies, Syngene International and Anthem Biosciences. Our technology platform is ideal for very cost-effective drug discovery and has the ability to enable early decision making as to the drugability of protein targets. The company is looking for collaborative opportunities with Biotechnology companies, virtual companies, Pharma companies, non-profit institutes and universities. All the IP rests with the sponsor of our research and any component of lead discovery from Sapient Discovery can be accessed in a fee-for-service fashion. We have completed several SBIR projects and a few are pending. We are currently servicing a few biotechnology companies in antibody structure determination and small molecule-protein crystal structure determination.

Molecular Health AG provides clinico-molecular informatic solutions. The firm’s approach allows doctors translate patient-specific molecular and genomic data, clinical history, and published scientific evidence into drug choices. The company was founded by Friedrich von Bohlen in 2004 and is headquartered in Basel, Switzerland.

Xencor provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for the treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy. The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant-negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.

Groupon is a deal-of-the-day website that offers discounted gift certificates usable at local or national companies. It is known as an online e-commerce platform that provides its users with the ability to purchase any product. Groupon offers consumers a vast marketplace of deals all over the world. Its users have the ability to discover various products on the web or on mobile with Groupon Local; enjoy vacations with Groupon Getaways; and find a curated selection of electronics, fashion, home furnishings, and more with Groupon Goods. Groupon provides merchants with a collection of products and services, including customizable deal campaigns, credit card payment processing capabilities, and point-of-sale solutions. The platform was launched in 2011 and is based in Chicago Heights, I.L.

ChoiceStream is a programmatic advertising partner that runs cross-device branding and direct response campaigns for brand and agency clients. ChoiceStream manages each phase of a campaign, from pre-launch planning to completion. By collecting poll-based, proprietary data specific to each client’s campaign, ChoiceStream creates custom, targetable audiences, optimizes results in real-time, and provides unique audience insight throughout each campaign. With world-class machine-learning algorithms and a dedicated team of in-house industry experts, ChoiceStream boasts an 83% client retention rate - well above the industry average. This combination of innovative technology and personalized service ensures that clients achieve their desired metrics. For more information on ChoiceStream,

Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment businesses; Connected Care businesses; Personal Health businesses; and Other. The Diagnosis and Treatment businesses segment consists systems, smart devices, software and services, powered by AI-enabled informatics-that support precision diagnoses and minimally invasive procedures in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care businesses segment consists Hospital Patient Monitoring, Emergency Care, Sleep & Respiratory Care and Connected Care Informatics. The Personal Health businesses segment consists of Oral Healthcare, Personal Care,Mother and Child Care. The Other segment reports on the items Innovation & Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.

Riva Health is building the future of cardiovascular healthcare. Riva’s breakthrough cardiology technology measures and manages hypertension, all through a smartphone app and camera. The company is led by co-founders, Dag Kittlaus and Tuhin Sinha, and confronts the leading cause of mortality in the United States, heart disease.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products.\nThe company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control.\nFounded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.